European approval for Roche's Tarceva as first-line in genetically distinct NSCLC
This article was originally published in Scrip
Executive Summary
Roche has received European approval of Tarceva as a first-line treatment in patients with a genetically distinct type of non-small cell lung cancer (NSCLC), continuing the company's progress in the field of personalised medicine.